Avastin

Avastin - most related articles:

- Avastin approved for brain cancer Glioblastoma - 6.9
- Avastin bevacizumab approval revoked to treat breast cancer in US - 6.5
- FDA panel votes to revoke approval for Avastin for advanced breast cancer - 6.1
- Avastin found effective in advanced breast cancer patients - 5.6
- Genentech's Avastin with chemotherapy approved for advanced breast cancer - 5.3
- Brain cancer vaccine prepared from brain tumor proves effective - 3.8

Avastin articles

Brain cancer vaccine prepared from brain tumor proves effective
A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme-which kills thousands of Americans every year.

Bevacizumab with chemotherapy provides no survival benefit for lung cancer patients
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) – an approach approved by the FDA in 2006 – did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare.

Avastin bevacizumab approval revoked to treat breast cancer in US
US health agency FDA Commissioner Margaret A. Hamburg, M.D. has revoked the approval of the breast cancer indication for Avastin (bevacizumab) after concluding that the drug has not been shown to be safe and effective for that use.

FDA panel votes to revoke approval for Avastin for advanced breast cancer
The Oncologic Drugs Advisory Committee, FDA, USA disapproved the Avastin which cited a lack of survival benefit. Now as two more trials have been analyzed -- neither showing a survival benefit -- the FDA stated that in the balance, the benefit did not outweigh the harm.

Avastin approved for brain cancer Glioblastoma
Genentech, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) for people with glioblastoma with progressive disease following prior therapy.

Genentech's Avastin with chemotherapy approved for advanced breast cancer
Genentech, Inc. (NYSE: DNA) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Avastin (bevacizumab), in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer.

Avastin found effective in advanced breast cancer patients
Genentech, Inc. (NYSE: DNA) announced that AVADO, a Roche-sponsored Phase III, placebo-controlled study evaluating Avastin® (bevacizumab) in combination with docetaxel chemotherapy met its primary endpoint of prolonging progression-free survival (PFS) in patients who had not received prior chemotherapy for their locally recurrent or metastatic HER2-negative breast cancer.

7 Avastin articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
4.49